CIML NK
Phase 1Cell therapy
CIML NK is one of 16 biologic programs targeting Hematopoietic Cell Transplantation. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Hematopoietic Cell Transplantation
#DrugCompanyPhaseTrials
1Pulmicort
SSalix
Phase 3
Fludara
SanofiPhase 2
Cellcept
RochePhase 2
Darzalex
Johnson & JohnsonPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Prograf
VVeloxis Pharmaceuticals
Phase 2
Busulfex
Akero TherapeuticsPhase 2
Alkeran
AApotex Inc.
Phase 2
Mesnex
BBaxter Healthcare Corporation
Phase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Memory1 trial
Hematopoietic Cell Transplantation1 trial
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Recruiting·—·Phase 1·NCT04024761·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CIML NK. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details